Tag: IBIO

Blue Horseshoe Stocks: Recap on RPRX, JNUG, Others

Repros Therapeutics, Inc. RPRX

The primary attraction to come off of our report on Friday was definitely RPRX. The stock had one heck of a solid session, building steadily all day long. It traded from a morning low of 7.66, and reached as high as 10.25 just prior to the close, and did so on volume which exceeded the 3-month average by nearly eight times. That’s a really impressive run from a stock in this price range.

We originally caught RPRX on October 17th after catching the stock gapping down to 52-week lows, and measuring from the low we observed subsequent to that report (5.97), Friday’s high represented an overall increase of 71%

The company is slated to release earnings today >> View Earnings Calendar

Direxion Daily Jr Gld Mnrs Bull 3X ETF (JNUG)

Also jumping off of Friday’s extended watchlist with a good showing was JNUG. We seemed to have timed our mention of this ETF quite well, with gold prices having bounced off of their annual low on Thursday, it set the stage for JNUG to make a respectable intraday day for us.

It traded in a range from 3.59-4.44, gaining as much as 24% on considerable volume, to the tune of 4.5X it’s 3-month average.

JNUG could be an interesting play moving forward providing the rebound in the price of gold is sustained, so that will be one of the things we’ll be interested to watch for as we kick off a new trading week.

Dendreon Corp. DNDN

DNDN is taking a massive premarket pounding this morning in the wake of the company’s filing for Chapter 11 protection. It’s worth noting, despite the forthcoming restructuring, the company will continue to produce and distribute its PROVENGE immunotherapy treatment, and has declared that it “has significant liquidity to support all of its operations during the restructuring process, with approximately $100 million of cash, cash equivalents and investments on hand as of November 7, 2014” >> View PR

Because of the nature of the situation, we’ll be exercising extreme caution, but we still want to monitor the stock for a bottom and subsequent bounceplay opportunities that could come as a result.

Extended Watchlist:
ACHN, IBIO, ARQL, DVAX, UEC, OIBR

Blue Horseshoe Stocks: APT, VTAE, NEWC & More

Alpha Pro Tech Ltd. APT 

Here’s a past gainer that began to catch our attention yesterday- We jumped on APT for the first time back on October 10th, while the stock was in the middle of a huge run. We observed the low of 5.72 on that day, and the stock took just two more sessions to reach a high of 10.73, marking a move of 87%

Following that big spike, APT had been beaten back over the past couple weeks, and this week, has begun to bounce off support above the 50DMA (3.58). We want to pay attention as the stock attempts a recovery.

Vitae Pharma, Inc. VTAE

We want to put VTAE on our radar as we close out the week, and keep an eye on it moving forward. The stock is gapping up big this morning; it had already been on the incline prior to yesterday’s news that really served to heat things up.

VTAE announced it had received positive results from a couple of its Phase-1 trials for an Alzheimer’s treatment they claim “Demonstrated Greater Than 80% Reduction of an Alzheimer’s Disease Biomarker” >> VIEW PR

The statement indicated that the results would lead to further trials over the next several months, so we’re going to enter VTAE into the log and reserve it a spot on our watchlists.

New Columbia Resources, Inc. NEWC

NEWC is a play we want to radar and add to our expansive marijuana-stock watchlist. We’re always keeping our eyes peeled for new cannabis stocks to watch, and we caught this one on a news scan today.

The company announced that its “Colombian subsidiary, Sannabis S.A.S., has legally produced  a trial run of cannabis based products on an Indian reservation.”

Infinera Corp. INFN

INFN appeared in yesterday’s report and made a decent move on strong volume, to the tune of nearly 10X the monthly average. The stock traded in a range from 12.17-13.96, a 15% intraday increase. We’ll be keeping watch over this play into next week as well.

Extended Watchlist:
OMEX, HEB, RUBI, IBIO

Blue Horseshoe Stocks: PZOO Update, Commenting on the Marijuana Sector

Pazoo, Inc. PZOO

So far we’ve been very happy with the way PZOO has performed since we brought it into the mix to start the week. Our assertion that the PZOO chart was on the cusp of making a nice move proved accurate; after starting out at a low of .0225 on Monday, the stock broke through its 50DMA and traded as high as .031 during yesterday’s session (+38%).

Volume picked up as well, with the stock trading 2.6M shares on the day, which works out to more than 3.5X the 3-month average.

So this new play that has us interested on a long-term basis (for reasons stated in our initial report) has also shown that it has some real short-term potential as well. We also caught a fresh PR this morning, which you’ll find below the following snapshot of the PZOO chart:

WHIPPANY, NJ–(Marketwired – Oct 22, 2014) – Pazoo, Inc. (OTCQB: PZOO) (German WKN#: A1J3DK) is pleased to announce its medical marijuana testing laboratory partner MA & Associates, LLC has hired its first lab technician, Mr. Brad Gore. Further, the build-out for the testing facility began last week. Now that the asbestos abatement was done, actual construction to the facility will begin.

MA & Associates, LLC felt it necessary to begin the build-out of the testing facility and to begin hiring all necessary personnel prior to the State of Nevada issuing licenses to qualified applicants on November 3rd >> FULL PR

PZOO is dually involved with the continued development of its health and wellness online portal at PAZOO.COM as well as its majority stake in a medical marijuana testing firm in Nevada. For those who might have missed our special report on the stock Monday, you can find a copy here: PZOO REPORT

Marijuana Sector Reminder

We also want to touch briefly on our ongoing interest in other medical and legal marijuana plays. For over two years we’ve tracked, and continue to monitor the sector as a whole, with huge winners coming in the form of MJNA, CBIS, HEMP, GRNH, TRTC, ERBB, and so many others.

We recently reminded everyone that we’d be on the lookout for the cannabis space to heat up as we approach a voting season with an unprecedented number of marijuana initiatives on ballots across the country.

This Monday, a federal court will hear evidence contesting that the US Government’s classification of marijuana as a Schedule 1 substance (which ridiculously makes it equal to heroin in the eyes of federal law) is unfounded. Several doctors are prepared to challenge the scientific and medical validity of government claims. If truth and reason win the day, it could be a big step toward  furthering the cause of cannabis acceptance nationwide. >>> READ ARTICLE

Extended Watchlist:
IBIO, RGLS, CLF, BBLU, ZAZA